C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 1.955 USD -3.46% Market Closed
Market Cap: 37.9m USD

EV/EBIT
Enterprise Value to EBIT

-0.8
Current
-0.7
Median
7.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.8
=
Enterprise Value
15.9m USD
/
EBIT
-21m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
C
Caladrius Biosciences Inc
LSE:0HS8
Average EV/EBIT: 46.5
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
NL
argenx SE
XBRU:ARGX
63.8
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.7
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.7
2-Years Forward
EV/EBIT
-0.5
3-Years Forward
EV/EBIT
-0.4